CHU de Quebec Hopital de l Enfant Jesus

Québec, Quebec G1R 2J6

0 studies enrolling now · 6 studies all time

What they study most

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers, Advanced Solid Tumors, Extensive Stage Small Cell Lung Cancer, Extensive-Stage Small-Cell Lung Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Kirsten Rat Sarcoma (KRAS) pG12C Mutation, Small Cell Lung Cancer, Small-Cell Lung Cancer

Studies at this site

• Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. — Stopped early
• A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) — Running, not enrolling
• Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) — Running, not enrolling
• First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) — Running, not enrolling
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Running, not enrolling
• Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) — Running, not enrolling